Latest Derivatives News

Ramsay Health Care announces a fully franked ordinary distribution of AUD 2.9642 per security on its perpetual preference shares, reflecting a steady income stream for investors. The payment is scheduled for April 2026, subject to board and external approvals.

Orthocell has boosted its investment in Marine Biomedical to secure exclusive global distribution rights for PearlBone™, an innovative bone substitute nearing FDA approval, enhancing its regenerative medicine portfolio.

Platina Resources has secured a conditional agreement to acquire the Sunrise Bore Gold Project, significantly expanding its landholding in Western Australia's prolific Laverton gold district. The project offers promising historical mineralisation and strong exploration potential near key regional mines.

GreenX Metals has uncovered a significant 1940 historical copper estimate of 728,000 tonnes at 2.6% grade from its Tannenberg Project in Germany, validated by a 1984 drilling campaign including silver by-product. The discovery supports a modern exploration model and sets the stage for a new drilling program to confirm and upgrade the resource.

De.mem Limited has acquired Core Chemicals Pty Ltd for $2.68 million, nearly doubling its EBITDA and positioning itself to capitalise on a surging gold sector. The deal combines strong recurring revenues with significant synergy potential.

Alkane Resources reports its inaugural JORC-compliant Mineral Resources and Ore Reserves for the Costerfield Property, highlighting a robust resource base and a mine life extended to 2030. The recent True Blue Deposit discovery further bolsters the project’s potential.

BlackRock Investment Management has released the estimated distribution components for its iShares S&P/ASX Dividend Opportunities ESG Screened ETF for the period ending 9 October 2025, highlighting key income sources and tax considerations.

ABx Group reports outstanding impurity removal results from bulk sample tests at its Deep Leads rare earth project, retaining over 98% of critical rare earths and advancing towards a mixed rare earth carbonate product sample in late 2025.

PYC Therapeutics has reported encouraging pre-clinical results for its RNA therapy candidate PYC-002 targeting Phelan-McDermid Syndrome, supporting plans to enter human trials in 2026. The data demonstrate safety, brain distribution, and gene expression restoration in key disease regions.

White Cliff Minerals has revealed promising airborne geophysical data identifying multiple new high-priority copper targets adjacent to the Danvers deposit in Nunavut, signaling significant exploration upside at the Rae Copper Project.

PMET Resources has successfully produced commercial-grade pollucite concentrate from its Shaakichiuwaanaan Project, revealing a promising pathway to valuable caesium co-products alongside lithium and tantalum.

Terra Critical Minerals (ASX – T92) has revealed extensive high-grade silver mineralisation across its 100% owned Mole River project in NSW, highlighting significant polymetallic potential and setting the stage for a major exploration push.